Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3results about "Growth hormones" patented technology

Long-acting coagulation factor vii and methods of producing same

A composition for use in treating a coagulation or clotting disorder, treating excessive bleeding or bruising, or maintaining homeostasis following a mild to moderate bleed in a subject, the composition comprising a human chorionic gonadotropin carboxy terminal peptide (CTP)-modified human active Factor VII (FVIIa) polypeptide comprising three CTP molecules attached in tandem to the C-terminal end of FVIIa and having the amino acid sequence of SEQ ID NO: 7, wherein the CTP-modified FVIIa polypeptide is in a substantially pure and active form, the CTP-modified FVIIa polypeptide having a high sialic acid content of at least 15 mol / mol
Owner:OPKO BIOLOGICS LTD

A method for preparing inclusion bodies based on dual promoter expression plasmids and its application

ActiveCN120624490BImprove broken rateHigh inclusion body contentVectorsBacteriaHuman Growth Hormone GeneDual promoter
This invention discloses a method for preparing inclusion bodies based on dual-promoter expression plasmids and its application, belonging to the field of biotechnology. The invention includes screening of totipotent nucleases, purification of totipotent nucleases, verification of the degradation activity of the totipotent nuclease DNS on nucleic acids, construction of dual-promoter recombinant strains, fermenter culture, cell recovery, and cell disruption to obtain crude inclusion bodies. This invention achieves high-efficiency expression of the recombinant human growth hormone gene induced by the T7 promoter and high-activity expression of the totipotent nuclease gene DNS induced by the cspA promoter, demonstrating significant effects in the application of recombinant human growth hormone. During the preparation process, the cell viscosity is low, the homogenization and disruption effect is improved, the BL21(DE3) / DGH cell disruption rate is high, the inclusion body content harvested by centrifugation per unit volume of fermentation broth is high, and the residual amount of HCD (host DNA residue) in the target protein per unit mass is reduced, effectively reducing energy consumption.
Owner:浙江毓昌生物技术有限公司